Ottimo Pharma is an innovative, clinical-stage, biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies to extend the lives of patients living with cancer.

Ottimo Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for OTP-01, a First-in-Class, Dual-Paratopic, Single-Agent, Anti-PD-1/VEGFR2 Antibody 7 January 2026 - First patient dosed and study open in leading oncology centers in US and Australia Phase I/IIA adaptive study aims to assess and optimize the dose of OTP-01 and provide safety, tolerability, and early efficacy data initially in patients known to benefit from PD-1 and/or VEGF treatment IND application data supports the potential of OTP-01 as […]
Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors 10 April 2025 - Ottimo Pharma (“Ottimo”), an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual paratopic antibodies to extend the lives of patients living with cancer, today announces the appointment of Roger Dansey, M.D., a prominent leader in oncology research and drug development, to its board of directors.